A Multidisciplinary Model Predicts Clinical Response in Relapsed Multiple Myeloma

被引：0
|
作者：
Shain, Kenneth H. [1 ]
Silva, Ariosto [2 ]
Meads, Mark B. [3 ]
Distler, Allison [3 ]
Jacobson, Timothy [2 ]
Gatenby, Robert [2 ]
Baz, Rachid [1 ]
Silva, Maria [4 ]
Rebatchouk, Dmitri [5 ]
Cubitt, Chris [4 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Intergrated Math Oncol, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] nPharmakon, Piscataway, NJ USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Therapy of relapsed and relapsed refractory multiple myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 113 - 113
  • [22] Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM).
    Rajkumar, SV
    Dispenzieri, A
    Lacy, M
    Geyer, S
    Iturria, N
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, R
    Greipp, PR
    Gertz, MA
    Witzig, TE
    BLOOD, 2001, 98 (11) : 162A - 163A
  • [23] Management of Relapsed and Relapsed/Refractory Multiple Myeloma
    Laubach, Jacob P.
    Mitsiades, Constantine S.
    Mahindra, Anuj
    Luskin, Marlise R.
    Rosenblatt, Jacalyn
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Avigan, David
    Raje, Noopur
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (10): : 1209 - 1216
  • [24] Therapy of relapsed multiple myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 12 - 12
  • [25] Therapy for relapsed multiple myeloma
    Aljama, Mohammed A.
    Sidiqi, M. Hasib
    Dingli, David
    PANMINERVA MEDICA, 2018, 60 (04) : 174 - 184
  • [26] Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide
    Prince, H. M.
    Schenkel, B.
    Mileshkin, L.
    LEUKEMIA, 2007, 21 (04) : 818 - 820
  • [27] Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide
    H M Prince
    B Schenkel
    L Mileshkin
    Leukemia, 2007, 21 : 818 - 820
  • [28] Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients
    Levacque, Zachary
    Rosales, Jesusa L.
    Lee, Ki-Young
    CELL CYCLE, 2012, 11 (21) : 4093 - 4095
  • [29] A Slow Pattern of Response in a Relapsed Multiple Myeloma Patient Treated with Lenalidomide
    Ramirez, G.
    de Llano, M. P.
    Campos, A.
    Rosell, A.
    Garcia, R.
    del Castillo, S.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S88 - S89
  • [30] Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma
    Mark, Tomer M.
    Allan, John N.
    Boyer, Angelique
    Rossi, Adriana C.
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    BLOOD, 2013, 122 (21)
12345